Biophytis Announces New Scientific Advisory Board for its Phase 2 OBA Clinical Study in Obesity

Biophytis SA (Euronext Growth Paris:ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specialized in the development of therapeutics for age-related diseases, today announces the formation of a new...

Related Keywords

Hebron ,Israel General ,Israel ,Cambridge ,Cambridgeshire ,United Kingdom ,Paris ,France General ,France ,Baylor College Of Medicine ,Texas ,United States ,Spain ,Massachusetts ,Houston ,Barcelona ,Comunidad Autonoma De Cataluna ,Michigan ,London ,City Of ,Veillet ,Rhôalpes ,Francisco Guarner ,Antoine Denry ,Dennis Villareal ,Nizar Berrada ,Dennist Villareal ,Nicolas Fellmann ,Digestive System Research Unit ,Exchange Commission ,Wellcome Research Laboratories Beckenham ,Baylor College Of Medicine Houston ,University Clinic Of Navarra ,Upjohn Company In Kalamazoo Michigan ,King College Hospital London ,Announces New Scientific Advisory Board ,Euronext Growth Paris ,Scientific Advisory Board ,Professor Dennis Villareal ,Professor Francisco Guarner ,Investigational New Drug ,Baylor College ,Medicine Houston ,Internal Medicine ,Hospital Clinic ,University Clinic ,Visiting Scientist ,Research Fellow ,Upjohn Company ,Royal Free Hospital ,College Hospital ,Wellcome Research Laboratories ,Experimental Laboratory ,University Hospital Vall ,Scientific Committee ,Research Institution ,Euronext Growth ,American Depositary Shares ,Nasdaq Capital Market ,